Generic Name and Formulations:
Naloxone HCl 0.4mg/0.4mL, 2mg/0.4mL; soln in a prefilled auto-injector for IM or SC inj; latex-free.
Indications for EVZIO:
Emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or CNS depression.
Adults and Children:
<1yr: Pinch thigh muscle while administering; monitor inj site for residual needle parts and/or infection. ≥1yr: Inject IM or SC into the anterolateral aspect of the thigh (through clothing, if necessary) according to label instructions. All: may give additional doses every 2–3 mins until desired response or emergency medical assistance available. Repeated doses depending on amount, type, and route of administration of the opioid being antagonized may be required.
Not a substitute for emergency medical care. Monitor patients with satisfactory response due to long duration of some narcotics. Have other resuscitative measures available. Known or suspected opioid dependence; abrupt reversal may precipitate acute withdrawal syndrome. Post-op use in pre-existing cardiac disorders; monitor. Neonates. Elderly. Pregnancy. Nursing mothers.
Caution with cardiotoxic drugs. Incomplete reversal of mixed agonists/antagonists (eg, buprenorphine, pentazocine); may require higher naloxone dose.
Dizziness, inj site erythema; precipitation of severe opioid withdrawal.
Prefilled auto-injectors—2 (w. Trainer)
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine